HAMPSTEAD, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Farmers and Merchants Bancshares, Inc. (the “Company”), the parent company of Farmers and Merchants Bank (the “Bank” and, together with the Company, “we”, “us” and “our”), announced that net income for the quarter ended March 31, 2025 was $1.2 million, or $0.37 per common share (basic and diluted), compared to $1.2 million, or $0.39 per common share (basic and diluted), for the same period in 2024. The Company’s return on average equity during the quarter ended March 31, 2025 was 8.22% compared to 9.40% for the same period in 2024. The Company’s return on average assets during the quarter ended March 31, 2025 was 0.57% compared to 0.61% for the same period in 2024.

SINGAPORE, April 29, 2025 (GLOBE NEWSWIRE) -- Ohmyhome Ltd. (NASDAQ: OMH), a one-stop-shop property technology platform offering end-to-end real estate solutions including brokerage, renovation, and condominium property management services in Singapore, today announced its audited financial results for the fiscal year ended December 31, 2024.

SINGAPORE, April 29, 2025 (GLOBE NEWSWIRE) -- JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a global technology company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission on April 29, 2025, Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.joyy.com.

Award demonstrates Cycurion’s growth in public, transportation sector through comprehensive IT and cybersecurity services offering

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy^® (semaglutide) through NovoCare^® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy^® directly within LifeMD’s virtual care platform.

SINGAPORE, April 29, 2025 (GLOBE NEWSWIRE) -- MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform, as well as a digital insurance brokerage provider in Greater Southeast Asia, today announced its financial results for the fourth quarter and full year ended December 31, 2024.

FREEHOLD, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, and YOOV Group Holding Limited (“YOOV”), a provider of highly advanced artificial intelligence (“AI”) automation solutions, jointly announced the filing with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form S-4 in connection with the proposed Merger (as defined below).

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025.

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Sysco Corporation (NYSE: SYY) (“Sysco” or the “company”) today announced financial results for its 13-week third fiscal quarter ended March 29, 2025.

Vaisala Corporation
Managers’ Transactions
April 29, 2025, at 3:00 p.m. (EEST)

CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA.

Two studies report favorable clinical outcomes and safety data for Renuvion^® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin

iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration

DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering). The closing of the Offering is expected to occur on or about April 30, 2025, subject to the satisfaction of customary closing conditions.

Media Release